EJNMMI Research

Table 1 Sensitivity of four human NSCLC cell lines to the anti-proliferative effect of erlotinib in vitro

From: Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [¹¹C]erlotinib PET

Cell line	Type of EGFR mutation	IC ₅₀ of erlotinib [μM]	Erlotinib sensitive
QG56	None (wtEGFR)	8.9 ± 0.5***	No
HCC827	Activating (delE746-A750)	0.004 ± 0.0009	Yes
NCI-H3255	Activating (L858R point mutation)	0.041 ± 0.007	Yes
NCI-H1975	Double mutation (L858R + T790M point mutations)	4.3 ± 0.8***	No

***p < 0.001 with respect to HCC827 cells.

Back to article page